https://www.selleckchem.com/pr....oducts/tolebrutinib-
The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing. The identification of risk factors for severe outcomes is important. Dyslipidemia has been shown as a long-known risk factor for cardiovascular disease. The aim of this study is to analyze the potential association between dyslipidemia and the severity of COVID-19 infection. We systematically searched the PubMed database using specific keywords related to our aims until July 9th, 2020. All articles published on COVID-19 an
Like
Comment
Share
